Skip to main content
. Author manuscript; available in PMC: 2021 Feb 1.
Published in final edited form as: Aliment Pharmacol Ther. 2019 Nov 22;51(4):435–445. doi: 10.1111/apt.15577

Figure 2: Pooled estimates from active intervention and placebo arms of ulcerative colitis clinical trials for prevalence of Mayo endoscopic scores during maintenance by patient reported outcome permutations.

Figure 2:

Figure 2:

Figure 2:

RBS: rectal bleedings core; SFS: stool frequency score; CI: Confidence interval Prevalence estimates are for the combined population of patients receiving active intervention (ie biologic or tofacitinib) or placebo. Individual study level estimates cannot be used to compare prevalence estimates across studies between different biologics or tofacitinib.

A: Endoscopic improvement (Mayo endoscopic score 0 or 1); B: Endoscopic remission (Mayo endoscopic scopre 0); C: Mild endoscopic activity (Mayo endoscopic score 1)